The United States Food and Drug Administration (FDA) could grant the emergency use of a coronavirus vaccine before the end of the first half of the month of December or at the start of the second half, said Biotech CEO, Ugur Shaheen quoted by the Reuters agency.
Indeed, pharmaceutical laboratories, Pfizer and Biontech, said that they could obtain approval by American and European regulators, next December, for the marketing of their COVVI-19 vaccine after the results of the final trial which showed a success rate of 95% and without any serious side effect.
This vaccine is even considered, currently as the vaccine with the highest success rate among all vaccines tested during recent clinical stages, according to the two partner laboratories.
